Immunome (IMNM) Non-Current Deffered Revenue (2019 - 2024)
Immunome (IMNM) posted Non-Current Deffered Revenue of $2.2 million for Q1 2024, down 59.77% on a QoQ basis from $5.5 million in Q4 2023, and down 76.56% year-over-year from $9.4 million in Q2 2023.
Immunome (IMNM) Non-Current Deffered Revenue (2019 - 2024) Analysis & Trends
Immunome's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $2.2 million for Q1 2024.
- Quarterly Non-Current Deffered Revenue fell 76.56% year-over-year to $2.2 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $2.2 million (down 76.56% YoY) and the FY2023 annual result came in at $5.5 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $2.2 million for Q1 2024 at Immunome, down from $5.5 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $9.4 million in Q1 2023 and bottomed at $3000.0 in Q2 2021.
- A 4-year average of $2.3 million and a median of $12000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue jumped 50.0% — and 2024, when it slumped 76.56%.
- Immunome's Non-Current Deffered Revenue stood at $8000.0 in 2020, then soared by 50.0% to $12000.0 in 2021, then surged by 45641.67% to $5.5 million in 2023, then sank by 59.77% to $2.2 million in 2024.
- Business Quant data shows IMNM's Non-Current Deffered Revenue at $2.2 million in Q1 2024, $5.5 million in Q4 2023, and $2.9 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immunome | 2.49 Bn | 1.91 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 5.49 Mn |
| Sep 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 5.71 Mn |
| Mar 31, 2023 | 9.42 Mn |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 5,000.00 |
| Dec 31, 2020 | 8,000.00 |
| Sep 30, 2020 | 11,000.00 |
| Dec 31, 2019 | 18,000.00 |